Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 15:24John Chuback: DVT Can Start With Symptoms Many People Brush Off
-
Jun 1, 2026, 15:20Venugopalan Unni: Guidelines for the Evaluation and Management of Acute Pulmonary Embolism in Adults
-
Jun 1, 2026, 15:10Smitirupa Mishra: Standardizing RBC Morphology Reporting – Why ICSH Guidelines Matter?
-
Jun 1, 2026, 14:54Davide Massimi: A Bloodless Approach to Third Space Endoscopy
-
Jun 1, 2026, 14:27Afshan Sumera: Plasma Proteomics Reveals Complement And Coagulation Disruption In Transfusion-Dependent Thalassemia
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting